{"groups":[{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 50 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"FG000","title":"Bendamustine 50 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 70 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"FG001","title":"Bendamustine 70 mg/m^2 Cohort"},{"description":"Bortezomib 1.0 mg/m\\^2/dose (days 1, 4, 8 and 11) by intravenous push and Bendamustine 90 mg/m\\^2/dose (days 1 and 4) intravenously for up to eight 28 day cycles.","id":"FG002","title":"Bendamustine 90 mg/m^2 Cohort"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"10"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Noncompliance to study medication"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}],"type":"Response plateau; started maintenance"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"31"}],"type":"Safety and Efficacy Populations"},{"achievements":[{"comment":"completed eight cycles of treatment","groupId":"FG000","numSubjects":"0"},{"comment":"completed eight cycles of treatment","groupId":"FG001","numSubjects":"1"},{"comment":"completed eight cycles of treatment","groupId":"FG002","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Fifty-one patients were screened and forty from 10 U.S. centers were enrolled. Reasons for not enrolling were failed to meet inclusion and/or exclusion criteria (10) and an adverse event (1)."}